Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing
Reexamination Certificate
2011-03-29
2011-03-29
Li, Bao (Department: 1648)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
C530S300000
Reexamination Certificate
active
07914780
ABSTRACT:
The present invention concerns compositions and methods for the treatment of cancer. More specifically, the present invention relates to identification of aminopeptidase A (APA) as a functional target in neo-vasculature, e.g., tumor vasculature; the present invention also relates to targeting peptides and antibodies specific for APA which may be used for cancer therapies.
REFERENCES:
patent: 4472509 (1984-09-01), Gansow et al.
patent: 4912040 (1990-03-01), Kaufman et al.
patent: 4931053 (1990-06-01), L'Esperance, Jr.
patent: 5021236 (1991-06-01), Gries et al.
patent: 5081034 (1992-01-01), Bevilasqua et al.
patent: 5098833 (1992-03-01), Lasky et al.
patent: 5188964 (1993-02-01), McGuire et al.
patent: 5206347 (1993-04-01), Ruoslahti et al.
patent: 5216131 (1993-06-01), Lasky et al.
patent: 5223409 (1993-06-01), Ladner et al.
patent: 5225538 (1993-07-01), Capon et al.
patent: 5259380 (1993-11-01), Mendes et al.
patent: 5270163 (1993-12-01), Gold et al.
patent: 5288846 (1994-02-01), Quertermous et al.
patent: 5304640 (1994-04-01), Lasky et al.
patent: 5336248 (1994-08-01), Good et al.
patent: 5415874 (1995-05-01), Bender et al.
patent: 5428130 (1995-06-01), Capon et al.
patent: 5453362 (1995-09-01), Lamarco et al.
patent: 5463026 (1995-10-01), Nakamura et al.
patent: 5464436 (1995-11-01), Smith
patent: 5492807 (1996-02-01), Santi
patent: 5506126 (1996-04-01), Seed et al.
patent: 5536814 (1996-07-01), Ruoslahti et al.
patent: 5585277 (1996-12-01), Bowie et al.
patent: 5622699 (1997-04-01), Ruoslahti et al.
patent: 5624962 (1997-04-01), Takeuchi et al.
patent: 5670312 (1997-09-01), Santi
patent: 5688692 (1997-11-01), Jat et al.
patent: 5688935 (1997-11-01), Stephens et al.
patent: 5705610 (1998-01-01), Zuckermann et al.
patent: 5750344 (1998-05-01), Doyle
patent: 5840841 (1998-11-01), Zuckermann et al.
patent: 5866759 (1999-02-01), Jat et al.
patent: 5902598 (1999-05-01), Chen et al.
patent: 5955572 (1999-09-01), Ruoslahti et al.
patent: 6057098 (2000-05-01), Buechler et al.
patent: 6068829 (2000-05-01), Ruoslahti et al.
patent: 6174861 (2001-01-01), O'Reilly et al.
patent: 6184973 (2001-02-01), Baer et al.
patent: 6215550 (2001-04-01), Baer et al.
patent: 6232440 (2001-05-01), Hillman et al.
patent: 6271196 (2001-08-01), O'Brien
patent: 6300064 (2001-10-01), Knappik et al.
patent: 6350855 (2002-02-01), Tobin
patent: 6399384 (2002-06-01), Jat
patent: 6458381 (2002-10-01), Sourovoi et al.
patent: 6528281 (2003-03-01), Tobin
patent: 6576239 (2003-06-01), Ruoslahti et al.
patent: 6881825 (2005-04-01), Robbins et al.
patent: 2001/0046498 (2001-11-01), Rouslahti et al.
patent: 2003/0113320 (2003-06-01), Ruoslahti et al.
patent: 2005/0191294 (2005-09-01), Arap et al.
patent: 19605175 (1997-08-01), None
patent: 0639584 (1998-04-01), None
patent: 4026631 (1992-01-01), None
patent: WO 92/00091 (1991-07-01), None
patent: WO 92/03461 (1992-03-01), None
patent: WO 92/06191 (1992-04-01), None
patent: WO 94/28424 (1994-12-01), None
patent: WO 95/14714 (1995-06-01), None
patent: WO 96/34874 (1996-11-01), None
patent: WO 96/34875 (1996-11-01), None
patent: WO 97/10507 (1997-03-01), None
patent: WO 97/19954 (1997-05-01), None
patent: WO 97/39021 (1997-10-01), None
patent: WO 98/10795 (1998-03-01), None
patent: WO 98/39469 (1998-09-01), None
patent: WO 99/04813 (1999-02-01), None
patent: WO 97/30024 (1999-09-01), None
patent: WO 99/46284 (1999-09-01), None
patent: WO 99/57311 (1999-11-01), None
patent: WO 00/14215 (2000-03-01), None
patent: WO 01/13114 (2000-08-01), None
patent: WO 01/42276 (2001-06-01), None
patent: WO 01/53342 (2001-07-01), None
patent: WO 02/02055 (2002-01-01), None
patent: WO 02/20722 (2002-03-01), None
patent: WO 02/20723 (2002-03-01), None
patent: WO 02/20769 (2002-03-01), None
patent: WO 02/20822 (2002-03-01), None
patent: WO 03/022991 (2003-03-01), None
Wu et al. J. Virology 2006, vol. 80, No. 22, pp. 11393-11397.
Miki et al. J. Biolog. Chemist. 1999, vol. 274, No. 41, pp. 29057-29062.
Deshayes et al. Biochemistry 2004, vol. 43, pp. 7698-7706.
Aiello et al., “Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins,”Proc. Natl. Acad. Sci., USA, 92(23):10457-10461, 1995.
Aiello et al., “Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders,”N. Eng. J. Med., 331(22):1480-1487, 1994.
Alliot et al., “Brain parenchyma vessels and the angiotensin system,”Brain Res., 830:101-112, 1999.
Alliot et al., “Pericytes and periendothelial cells of brain parenchyma vessels co-express aminopeptidase N, aminopeptidase A, and nestin,”J. Neurosci. Res., 58:367-378, 1999.
Alon et al., “Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity,”Nat. Med., 1:1024-1028, 1995.
Alonso and Maroto, “Plants as ‘chemical factories’ for the production of polyunsaturated fatty acids,”Biotechnology Advances, 18:481-497, 200.
Andrade et al., “Angiotensin-Il-induced angiogenesis in sponge implants in mice,”Int. J. Microcirc. Clin. Exp., 16(6):302-307, 1996.
Arap et al., Steps toward mapping the human vasculature by phage display,Nature Med., 8(2):121-127, 2002.
Arap et al., “Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model,”Science, 279:377-380, 1998.
Arap et al., “Cell surface expression of the stress response chaperone GRP78 enables tumor targeting by circulating ligands,”Cancer Cell, 6:275-284, 2004.
Arap et al., “Chemotherapy targeted to tumor vasculature ,”Curr. Opin. Onclol., 10(6):560-565, 1998.
Arap et al., “Targeting the prostate for destruction through a vascular address,”Proc. Natl. Acad. Sci., USA, 99:1527-1531, 2002.
Arden, “The absence of diabetic retinopathy in patients with retinitis pigmentosa: implications for pathophysiology and possible treatment.,”Br. J. Ophthalmol., 85:366-370, 2001.
Asako et al., “Organic solvent tolerance and antibiotic resistance increased by overexpression of marA inEscherichia coli,” Applied Environmental Microbiology, 63(4):1428-1433, 1997.
Assmann et al., “A nephritogenic rat monoclonal antibody to mouse aminopeptidase A. Induction of massive albuminuria after a single intravenous injection,”J. Exp. Med., 175:623-635, 1992.
Atkins et al., “Coordinated cytokine expression by stromal and hematopoietic cells during human osteoclast formation,”Bone, 26(6):653-661, 2000.
Baillie et al., “Tumor vasculature-A potential therapeutic target,”British J. Cancer, 72:257-267, 1995.
Baringa, “Peptide-guided cancer drugs show promise in mice,”Science, 279:323-324, 1998.
Baumann et al., “Complex of the soluble IL-11 receptor and IL-11 acts as IL-6-type cytokine in hepatic and nonhepatic cells,”J. Immunol., 157(1):284-290, 1996.
Beckman et al., “Experimental manipulation of the rodent visceral yolk sac,”Teratology, 41(4):395-404, 1990.
Behm et al., “Human homologue of the rat chondroitin sulfate proteoglycan, NG2, detected by monoclonal antibody 7.1, identifies childhood acute lymphoblastic leukemias with t(4;11)(q21;q23) or t(11;19)(q23;13) and MLL gene rearrangements,”Blood, 87:1134-1139, 1996.
Bergelson et al., “Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5,”Science, 275:1320-1322, 1997.
Bergers et al., “Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors,”J. Clin. Invest., 111(9):1287-1295, 2003.
Bicknell, “Vascular targeting and the inhibition of angiogenesis,”Annals of Oncology, 5(Suppl 4):S45-S50, 1994.
Bigner et al., “Phase I studies of treatment of malignant gliomas and neoplastic meningitis with 131I-radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroti
Arap Wadih
Pasqualini Renata
Board of Regents , The University of Texas System
Fulbright & Jaworski L.L.P.
Li Bao
LandOfFree
Aminopeptidase A (APA) targeting peptides for the treatment... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Aminopeptidase A (APA) targeting peptides for the treatment..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Aminopeptidase A (APA) targeting peptides for the treatment... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2740487